Market News & Trends
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
MetrioPharm AG recently announced the US FDA has granted Orphan Drug Designation for MP1032 for the treatment of Duchenne muscular dystrophy. DMD is the most…
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
Silo Pharma, Inc. recently announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated…
LIXTE Biotechnology’s Lead Clinical Compound Increases Effectiveness of Cancer Immunotherapy
LIXTE Biotechnology Holdings, Inc. recently announced a recently published article in the journal Cancer Research showed that PP2A, the pharmacologic target of LIXTE’s lead clinical…
Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell & Gene Therapy Development
Catalent recently announced it has expanded the services and capabilities at its facility in Shiga, Japan, to include the storage, kitting, and distribution of advanced…
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
Apellis Pharmaceuticals, Inc. recently announced the Phase 2 MERIDIAN study investigating systemic pegcetacoplan for the treatment of amyotrophic lateral sclerosis (ALS) did not meet its…
Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of Highly Differentiated Antibiotic for Severe Hospital Infections
Antabio SAS recently announces dosing of the first subjects in its Phase 1 clinical trial of MEM-ANT3310, a next- generation antibacterial combination that has been…
BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.
BriaCell Therapeutics Corp. recently announce it has entered into an arrangement agreement dated May 24, 2023, with BriaPro Therapeutics Corp. (SpinCo) pursuant to which certain…
Revvity Announces New License Agreement for Next-Generation Base Editing Technology
Revvity, Inc. recently announced a new license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a…
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
ImmunOs Therapeutics AG recently announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia. IOS-1002 is a…
Alvotech & Advanz Pharma Extend Strategic Partnership to Commercialize Five Proposed Biosimilars in Europe
Alvotech and Advanz Pharma recently announced the companies have entered into an exclusive partnership agreement regarding the supply and commercialization of five biosimilar candidates in…
EXCLUSIVE ONLINE CONTENT
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….